Drug Database
Back to search

Poland· PL-100235964

Relistor

A methylnaltrexone bromide product containing methylnaltrexoni bromidum, registered in Poland by Bausch Health Ireland Ltd.. The same ATC class is registered in 11 of our 19 countries.

ATC A06AH01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedRelistorATCA06AH01REGISTER NO.PL-100235964PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about methylnaltrexoni bromidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Methylnaltrexone bromide is registered in 11 of 19 countries.

Countries holding a registration under ATC A06AH01 (methylnaltrexone bromide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search methylnaltrexone bromide products by name

Methylnaltrexone bromide · ATC A06AH01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Methylnaltrexoni bromidum
Manufacturer
Bausch Health Ireland Ltd.
Country
Poland (PL)
ATC code
A06AH01
ATC class
Methylnaltrexone bromide
Defined daily dose
6 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

  • gtin
    05909990818549
  • gtin
    05909990818556
  • gtin
    05909990818563
  • gtin
    05909990818570

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

13 interactions on record for methylnaltrexone bromide.

Graded by severity as the source publishes them — 13 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check methylnaltrexone bromide against other medicinesHow interaction checks work

Methylnaltrexone bromide · interactions on record

13 records

  • 13 moderate

Most severe, free to view

  • AlvimopanA06AH02moderate
  • NaloxegolA06AH03moderate
  • NaloxoneA06AH04moderate
  • NaldemedineA06AH05moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Methylnaltrexone bromide in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All methylnaltrexone bromide products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Relistor
  • Iceland · Relistor
  • Liechtenstein · Relistor
  • Norway · Relistor

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/940f09dd-9cb1-4c05-924a-817a7662bea5
GET /v1/drugs/940f09dd-9cb1-4c05-924a-817a7662bea5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "12 mg",
  "packaging": "05909990818549 ¦ Rp ¦ EU/1/08/463/008 ¦ 61813\n4 amp.-strzyk. 0,6 ml\n05909990818556 ¦ Rp ¦ EU/1/08/463/009 ¦ 61814\n7 amp.-strzyk. 0,6 ml\n05909990818563 ¦ Rp ¦ EU/1/08/463/010 ¦ 61815\n8 amp.-strzyk. 0,6 ml\n05909990818570 ¦ Rp ¦ EU/1/08/463/011 ¦ 61816\n10 amp.-strzyk. 0,6 ml",
  "substance": "Methylnaltrexoni bromidum 12 mg",
  "common_name": "Methylnaltrexoni bromidum",
  "pl_product_id": "100235964",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about methylnaltrexone bromide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console